Clinical Trials on Spontaneous Remission in Canada

Total 80 results

Zimmer Biomet

Recruiting

Comprehensive Segmental Revision System

Rheumatoid Arthritis | Trauma | Oncology | Degenerative Disease | Revision Surgery

Canada, Denmark, United Kingdom
Sunnybrook Health Sciences Centre
Ontario Ministry of Health and Long Term Care; Sault Area Hospital; Scarborough... and other collaborators

Completed

Ontario ICU Clinical Best Practices Demonstration Project

Catheter Related Blood Stream Infections | Ventilator Acquired Pneumonia | Pressure Ulcer Prophylaxis | DVT Prophylaxis | Restrictive Blood Transfusion Strategy | Daily Spontaeous Breathing Trials

Canada
Novartis Pharmaceuticals

Completed

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Chronic Spontaneous Urticaria

United States, Spain, Germany, Taiwan, Japan, Australia, Russian Federation, Greece, Canada, United Kingdom
Allakos Inc.

Recruiting

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Healthy Participants | Chronic Spontaneous Urticaria

United States, Canada
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Argentina, Hungary, Thailand, Turkey, Malaysia, Canada, Bulgaria, Slovakia, Brazil, Poland
Novartis Pharmaceuticals

Completed

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Germany, Hungary, Spain, France, Turkey, Canada, Czechia, Netherlands, Poland, Japan, Russian Federation, Argentina, Denmark, Slovakia
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Osteosarcoma | Lymphoblastic Lymphoma | Recurrent Lymphoma | Recurrent Malignant Neoplasm | Hodgkin Lymphoma in Remission | Leukemia in Remission | Recurrent Leukemia

United States, Australia, Canada, Puerto Rico
Zimmer Biomet

Active, not recruiting

Comprehensive Nano - Post Market Clinical Follow-Up Study

Osteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Correction of Functional Deformity | Revision

Korea, Republic of, Canada, United Kingdom, Austria
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, South Africa, Chile, Canada
Escient Pharmaceuticals, Inc

Recruiting

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Chronic Spontaneous Urticaria

Spain, United States, Germany, Canada, Poland, Netherlands
Sanofi

Completed

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

Chronic Spontaneous Urticaria

Chile, Taiwan, Argentina, Germany, Canada, Russian Federation, Netherlands, Korea, Republic of, Spain, Greece, Italy, Japan, Poland
Novartis Pharmaceuticals

Completed

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria

Spain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Chronic Spontaneous Urticaria

China, France, Spain, Argentina, Germany, Japan, United States, Canada, Hungary, Russian Federation, United Kingdom
Amgen

Completed

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (INCEPTION)

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, Italy, Canada, Poland, Japan, France, Greece, Germany
Conceptra Biosciences, LLC

Recruiting

CCT-102 vs. Expectant Management in Delayed Pregnancy Loss (MERMAID)

Early Pregnancy Loss, Delayed Pregnancy Loss

United States
Novartis Pharmaceuticals

Completed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Hungary, Spain, France, Turkey, Canada, Czechia, Russian Federation, Poland, Japan, Argentina, Denmark, Slovakia
Spanish Society of Cardiology

Unknown

Spanish Registry on Spontaneous Coronary Artery Dissection (SR-SCAD)

Spontaneous Coronary Artery Dissection

Spain
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Childhood Acute Lymphoblastic Leukemia in Remission

United States, Canada, Australia
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

United States, Hungary, Taiwan, Spain, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
Novartis Pharmaceuticals

Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Chronic Spontaneous Urticaria

United States, Croatia, Hungary, India, Malaysia, Spain, Germany, Austria, Czechia, Denmark, France, Korea, Republic of, Greece, Singapore, Thailand, Bulgaria, Argentina, Turkey, Guatemala, Brazil, Russian Federation, Peru, Canada, Sw... and more
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Novartis Pharmaceuticals

Completed

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Chronic Spontaneous Urticaria

United States, Poland, Spain, Belgium, Germany, Russian Federation, Taiwan, Netherlands, Italy, Australia, France, Israel, Lebanon, Slovakia, India, Japan, Estonia, Philippines, Mexico, Argentina, United Kingdom, Vietnam, Brazil, Romania and more
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Chronic Spontaneous Urticaria

United States, Spain, Belgium, Croatia, Germany, Hungary, India, Malaysia, Russian Federation, Taiwan, Turkey, Netherlands, Italy, Australia, Israel, Korea, Republic of, Lebanon, Greece, Singapore, Slovakia, Thailand, Austria, Bulgaria and more
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
National Cancer Institute (NCI)

Terminated

Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia and other conditions

Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Childhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia
Target PharmaSolutions, Inc.

Recruiting

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC (TARGET-DERM)

Psoriasis | Atopic Dermatitis | Vitiligo | Hidradenitis Suppurativa | Alopecia Areata | Chronic Spontaneous Urticaria

United States, Spain, Canada, Germany
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Fungal Infection | Neutropenia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent Childhood Acute Myeloid... and other conditions

United States, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

Unspecified Childhood Solid Tumor, Protocol Specific | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Mucositis | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous... and other conditions

United States, Canada, Australia

Clinical Trials on Spontaneous Remission in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations